At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
Molgramostim nebuliser solution +1 moredrug
Likely dose
Molgramostim nebuliser solution 300μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID)
In Brief
A Phase 2 clinical trial evaluating Molgramostim nebuliser solution and Placebo nebuliser solution for Severe Acute Respiratory Syndrome (SARS) Pneumonia and COVID-19 Pneumonia. Completed, enrolled 63 participants across 9 sites.
Detailed Summary
To assess the safety and tolerability of inhaled molgramostim nebuliser solution in patients with COVID-19 pneumonia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartSep 2020
First PostedSep 2020
Primary CompletionJun 2022
Study CompletionSep 2022
TodayJul 2026
First PostedSep 30, 2020
Enrollment StartSep 24, 2020
Primary CompletionJun 21, 2022
Study CompletionSep 20, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.8 years ago
Interventions
Molgramostim nebuliser solutiondrug
300μg molgramostim nebuliser solution nebulised seven times within 7 days via rapid nebuliser system
Placebo nebuliser solutionother
Placebo nebulised seven times within 7 days via rapid nebuliser system